Reading AYTU? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track AYTU free→Reading AYTU? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track AYTU free→QuarterlyIQ Insights · AYTU
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(25.0) + peer(0.2*-25.0) + term(0.0) → 3.75% (capped ±15.0)
Calibrated likelihood the company misses analyst consensus on its next print, read from its own miss history plus its industry base rate. A fundamental tilt, not a price call — and a quiet watch-flag, not an alarm.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Calibrated. Base rate ~24%.
Consecutive quarters it missed, most recent run.
How often this industry misses, baseline.
Industry peers that missed in the recent window.
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Condition. On May 13, 2026, Aytu BioPharma, Inc. (the “Company”) issued a press release announcing its fiscal 2026 third quarter operational and financial results. As indicated in the press release, the Company scheduled a conference call and live audio webcast for May 13, 2026, at 4:30 p.m. Eastern time to discuss the operational and financial results and to answer questions. The conference call is publicly accessible via webcast and telephone (available l…
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Results of Operations and Financial Condition. See the disclosures in
Results of Operations and Financial Condition. On February 3, 2026, Aytu BioPharma, Inc. (the “Company”) issued a press release announcing its fiscal 2026 second quarter operational and financial results. As indicated in the press release, the Company scheduled a conference call and live audio webcast for February 3, 2026, at 4:30 p.m. Eastern time to discuss the operational and financial results and to answer questions. The conference call is publicly accessible via webcast and telephone (av…
Results of Operations and Financial Condition. On November 13, 2025, Aytu BioPharma, Inc. (the “Company”) issued a press release announcing its fiscal 2026 first quarter operational and financial results. As indicated in the press release, the Company scheduled a conference call and live audio webcast for November 13, 2025, at 4:30 p.m. Eastern time to discuss the operational and financial results and to answer questions. The conference call is publicly accessible via webcast and telephone (a…
Results of Operations and Financial Condition. On September 23, 2025, Aytu BioPharma, Inc. (the “Company”) issued a press release announcing its fiscal 2025 full year and fourth quarter operational and financial results. As indicated in the press release, the Company scheduled a conference call and live audio webcast for September 23, 2025, at 4:30 p.m. Eastern time to discuss the operational and financial results and to answer questions. The conference call is publicly accessible via webcast…
Results of Operations and Financial Condition. On May 14, 2025, Aytu BioPharma, Inc. (the “Company” or “Aytu”) issued a press release announcing its fiscal 2025 third quarter operational and financial results. As indicated in the press release, the Company scheduled a conference call and live audio webcast for May 14, 2025, at 4:30 p.m. Eastern time to discuss the operational and financial results and to answer questions. The conference call is publicly accessible via webcast and telephone (a…
Results of Operations and Financial Condition. On February 12, 2025, Aytu BioPharma, Inc. (the “Company” or “Aytu”) issued a press release announcing its fiscal 2025 second quarter operational and financial results. As indicated in the press release, the Company scheduled a conference call and live audio webcast for February 12, 2025, at 4:30 p.m. Eastern time to discuss the operational and financial results and to answer questions. The conference call is publicly accessible via webcast and t…